{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:32:59Z","timestamp":1793309579039,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.jpba.2026.117760","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:17:29Z","timestamp":1791645449000},"page":"117760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeted mass spectrometry for absolute quantification of total human \u03b2\u2011nerve growth factor in the development of a bispecific therapeutic antibody"],"prefix":"10.1016","volume":"283","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1623-4787","authenticated-orcid":false,"given":"Zhiling","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7552-3485","authenticated-orcid":false,"given":"Enowmpey","family":"Enowtambong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1132-9015","authenticated-orcid":false,"given":"Weiping","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2026.117760_bib1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.neuro.24.1.677","article-title":"Neurotrophins: roles in neuronal development and function","volume":"24","author":"Huang","year":"2001","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.jpba.2026.117760_bib2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0959-4388(96)80010-9","article-title":"Role of neurotrophic factors in neuronal development","volume":"6","author":"Henderson","year":"1996","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.jpba.2026.117760_bib3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13046-016-0395-y","article-title":"Nerve growth factor: role in growth, differentiation and controlling cancer cell development","volume":"35","author":"Aloe","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2026.117760_bib4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.neuro.29.051605.112929","article-title":"Neurotrophins: mediators and modulators of pain","volume":"29","author":"Pezet","year":"2006","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.jpba.2026.117760_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.tips.2005.12.001","article-title":"Novel class of pain drugs based on antagonism of NGF","volume":"27","author":"Hefti","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jpba.2026.117760_bib6","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.joca.2013.06.004","article-title":"Nerve growth factor: an update on the science and therapy","volume":"21","author":"Seidel","year":"2013","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.jpba.2026.117760_bib7","first-page":"373","article-title":"Anti-nerve growth factor in pain management: current evidence","volume":"9","author":"Chang","year":"2016","journal-title":"J. Pain. Res."},{"key":"10.1016\/j.jpba.2026.117760_bib8","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa0901510","article-title":"Tanezumab for the treatment of pain from osteoarthritis of the knee","volume":"363","author":"Lane","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2026.117760_bib9","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.pain.2011.05.003","article-title":"Efficacy and safety of tanezumab in the treatment of chronic low back pain","volume":"152","author":"Katz","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.jpba.2026.117760_bib10","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1212\/WNL.0000000000000686","article-title":"Fulranumab for treatment of diabetic peripheral neuropathic pain: a randomized controlled trial","volume":"83","author":"Wang","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jpba.2026.117760_bib11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/art.39943","article-title":"Long-term safety and efficacy of fulranumab in patients with moderate-to-severe osteoarthritis pain: a phase II randomized, double-blind, placebo-controlled extension study","volume":"69","author":"Sanga","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jpba.2026.117760_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/annrheumdis-2020-217259","article-title":"Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II\/III randomised clinical trial","volume":"80","author":"Dakin","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jpba.2026.117760_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1515\/revneuro-2022-0037","article-title":"Involvement of nerve growth factor (NGF) in chronic neuropathic pain - a systematic review","volume":"34","author":"Reis","year":"2023","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.jpba.2026.117760_bib14","first-page":"11","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Phase 2a Study of the Efficacy and Safety of a Bispecific Fusion Protein (MEDI7352) Targeting NGF and TNF\u03b1 in Patients with Painful Diabetic Neuropathy","volume":"2025","author":"Scott","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.jpba.2026.117760_bib15","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.4155\/bio-2016-0184","article-title":"Fit-for-purpose biomarker immunoassay qualification and validation: three case studies","volume":"8","author":"Cowan","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2026.117760_bib16","article-title":"Development and validation of brain-derived neurotrophic factor measurement in human urine samples as a non-invasive effect biomarker","volume":"15","author":"Olivas-Martinez","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.jpba.2026.117760_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jpba.2011.09.004","article-title":"Model-based strategy for bioanalytical method comparison: measurement of a soluble ligand as a biomarker","volume":"58","author":"Thway","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117760_bib18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jpba.2012.06.039","article-title":"Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarker","volume":"70","author":"Kanefendt","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117760_bib19","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jpba.2008.07.012","article-title":"A novel method for quantitative measurement of a biomarker in the presence of a therapeutic monoclonal antibody directed against the biomarker","volume":"48","author":"Davis","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117760_bib20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jpba.2009.06.043","article-title":"Immunoassay-based measurement of clinical biomarkers for monitoring changes in nasal cavity","volume":"50","author":"Zhang","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117760_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/rcm.8817","article-title":"FGF-21 biomarker detection at the sub-nanogram per mL level in human serum using normal-flow liquid chromatography\/tandem mass spectrometry","volume":"34","author":"Gao","year":"2020","journal-title":"Rapid Commun. Mass. Spectrom."},{"key":"10.1016\/j.jpba.2026.117760_bib22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4155\/bio-2018-0277","article-title":"Critical reagent screening and characterization: benefits and approaches for protein biomarker assays by hybrid LC\u2013MS","volume":"11","author":"Santockyte","year":"2019","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2026.117760_bib23","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.3390\/molecules28083311","article-title":"Development of a Highly Sensitive Hybrid LC\/MS Assay for the Quantitative Measurement of CTLA-4 in Human T Cells","volume":"28","author":"Wei","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.jpba.2026.117760_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114639","article-title":"Incorporating protein precipitation to resolve hybrid IP-LC-MS assay interference for ultrasensitive quantification of intact therapeutic insulin dimer in human plasma","volume":"212","author":"Sun","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117760_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116396","article-title":"An optimized UPLC-MS\/MS method for human plasma amyloid-\u03b2 42 and 40 measurement and application in Alzheimer's disease diagnosis","volume":"250","author":"Zhang","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117760_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/adt.2020.1024","article-title":"A flexible multiplatform bioanalytical strategy for measurement of total circulating shed target receptors: application to soluble B cell maturation antigen levels in the presence of a bispecific antibody drug","volume":"19","author":"Stauffer","year":"2021","journal-title":"Assay. Drug. Dev. Technol."},{"key":"10.1016\/j.jpba.2026.117760_bib27","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.4155\/bio-2017-0152","article-title":"Immunoaffinity LC\u2013MS\/MS for quantitative determination of a free and total protein target as a target engagement biomarker","volume":"9","author":"Zhang","year":"2017","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2026.117760_bib28","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/clinchem\/hvz022","article-title":"Protein Biomarker Quantification by Immunoaffinity Liquid Chromatography-Tandem Mass Spectrometry: Current State and Future Vision","volume":"66","author":"Neubert","year":"2020","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jpba.2026.117760_bib29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.aca.2020.06.023","article-title":"Fit-for-purpose protein biomarker assay validation strategies using hybrid immunocapture-liquid chromatography-tandem-mass spectrometry platform: Quantitative analysis of total soluble cluster of differentiation 73","volume":"1126","author":"Zhao","year":"2020","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jpba.2026.117760_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0304-3940(03)00403-8","article-title":"Nerve growth factor serum concentrations in healthy human volunteers: physiological variance and stability","volume":"344","author":"Lang","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jpba.2026.117760_bib31","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1021\/ac303031q","article-title":"Sequential protein and peptide immunoaffinity capture for mass spectrometry-based quantification of total human beta-nerve growth factor","volume":"85","author":"Neubert","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2026.117760_bib32","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4155\/bio-2015-0022","article-title":"Large-scale implementation of sequential protein and peptide immunoaffinity enrichment LC\/nanoLC-MS\/MS for human beta-nerve growth factor","volume":"8","author":"Schultz","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2026.117760_bib33","article-title":"Albiflorin: a promising natural monoterpene glycoside with potential therapeutic benefits for multiple physiological systems","volume":"2","author":"Li","year":"2025","journal-title":"Food Med. Homol."},{"key":"10.1016\/j.jpba.2026.117760_bib34","article-title":"The history, beneficial ingredients, mechanism, processing, and products of Panax ginseng for medicinal and edible value","volume":"2","author":"Zhang","year":"2025","journal-title":"Food Med. Homol."},{"key":"10.1016\/j.jpba.2026.117760_bib35","series-title":"M10 Bioanalytical Method Validation and Study Sample Analysis: Guidance for Industry","author":"U.S. Food and Drug Administration","year":"2022"},{"key":"10.1016\/j.jpba.2026.117760_bib36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1208\/s12248-022-00707-z","article-title":"R. Steenwyk. Biomarker Assay Validation by Mass Spectrometry","volume":"24","author":"Fernandez-Metzler","year":"2022","journal-title":"AAPS J."},{"key":"10.1016\/j.jpba.2026.117760_bib37","first-page":"43","article-title":"An improved rapid and highly sensitive enzyme immunoassay for nerve growth factor","volume":"1","author":"Hellweg","year":"1989","journal-title":"Technique"},{"key":"10.1016\/j.jpba.2026.117760_bib38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1208\/s12248-011-9251-3","article-title":"C. Rogers. Bioanalytical approaches to quantify \"total\" and \"free\" therapeutic antibodies and their targets: technical challenges and PK\/PD applications over the course of drug development","volume":"13","author":"Lee","year":"2011","journal-title":"AAPS J."},{"key":"10.1016\/j.jpba.2026.117760_bib39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1208\/s12248-023-00848-9","article-title":"S. K. Fischer. Overcoming Soluble Target Interference in Measurement of Total Bispecific Therapeutic Antibody Concentrations","volume":"25","author":"Shim","year":"2023","journal-title":"AAPS J."},{"key":"10.1016\/j.jpba.2026.117760_bib40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1074\/mcp.M900254-MCP200","article-title":"An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers","volume":"9","author":"Whiteaker","year":"2010","journal-title":"Mol. Cell. Proteom."},{"key":"10.1016\/j.jpba.2026.117760_bib41","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.cll.2011.07.004","article-title":"Peptide immunoaffinity enrichment coupled with mass spectrometry for peptide and protein quantification","volume":"31","author":"Whiteaker","year":"2011","journal-title":"Clin. Lab. Med."},{"key":"10.1016\/j.jpba.2026.117760_bib42","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M111.015347","article-title":"Sequential multiplexed analyte quantification using peptide immunoaffinity enrichment coupled to mass spectrometry","volume":"11","author":"Whiteaker","year":"2012","journal-title":"Mol. Cell. Proteom."},{"key":"10.1016\/j.jpba.2026.117760_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4155\/bio.11.286","article-title":"Pellet digestion: a simple and efficient sample preparation technique for LC-MS\/MS quantification of large therapeutic proteins in plasma","volume":"4","author":"Ouyang","year":"2012","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2026.117760_bib44","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.4155\/bio-2017-0105","article-title":"2D-LC\u2013MS\/MS to measure cleaved high-molecular-weight kininogen in human plasma as a biomarker for C1-INH-HAE","volume":"9","author":"Zhang","year":"2017","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2026.117760_bib45","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1471-4159.1989.tb01867.x","article-title":"Isolation and sequence of a cDNA clone of beta-nerve growth factor from the guinea pig prostate gland","volume":"52","author":"Schwarz","year":"1989","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jpba.2026.117760_bib46","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2459795","article-title":"Quantifying antibody binding: techniques and therapeutic implications","volume":"17","author":"Lodge","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.jpba.2026.117760_bib47","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/psp4.12169","article-title":"AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies","volume":"6","author":"Stein","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.jpba.2026.117760_bib48","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/joor.12977","article-title":"Daytime changes of salivary biomarkers involved in pain","volume":"47","author":"Jasim","year":"2020","journal-title":"J. Oral. Rehabil."},{"key":"10.1016\/j.jpba.2026.117760_bib49","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/psp4.13015","article-title":"Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor","volume":"12","author":"Shoji","year":"2023","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.jpba.2026.117760_bib50","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1208\/s12248-026-01298-9","article-title":"A novel neutralizing-antibody assay for detection of beta-NGF binding domain-specific antibodies against a beta-NGF\/TNFR2 bispecific therapeutic antibody","volume":"28","author":"Moshkovich","year":"2026","journal-title":"AAPS J."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526004280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526004280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:25:23Z","timestamp":1793309123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526004280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":50,"alternative-id":["S0731708526004280"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117760","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted mass spectrometry for absolute quantification of total human \u03b2\u2011nerve growth factor in the development of a bispecific therapeutic antibody","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117760"}}